Streetbeat News

Products Services

TSN

Tyson Foods, Inc. (NYSE:TSN) plans to reintroduce certain antibiotics, specifically ionophores, into its chicken supply chain by the end of the year. This move is expected to be cost-saving for Tyson, as consumers show less willingness to pay extra for antibiotic-free products. The FDA supports limited antibiotic use in meat production, noting that antibiotics like ionophores represent a significantly lower risk of developing drug-resistant bacteria. Tyson's shares are up 0.37% at $51.23 during the premarket session.

Portfolio Pulse from Vandana Singh

July 03, 2023 | 1:02 pm

ZTS

The FDA has announced that Zoetis has developed a new dosing syringe for Sileo, which is expected to become available in 2024.

Portfolio Pulse from Happy Mohamed

July 03, 2023 | 12:57 pm

AMD

META

NVDA

San Francisco-based startup MosaicML has conducted a test comparing AI chips from Nvidia Corp (NVDA) and Advanced Micro Devices Inc (AMD), finding that AMD's chips are about 80% as fast as Nvidia's. The test used AMD's MI250 and Nvidia's A100 chips, with AMD's performance boosted by a new version of AMD software and open-source software backed by Meta Platforms Inc (META) called PyTorch. MosaicML believes that further software updates from AMD could help its MI250 chip match the performance of Nvidia's A100.

Portfolio Pulse from Anusuya Lahiri

July 03, 2023 | 12:47 pm

RMED

Ra Medical Systems has announced its plans to expand distribution outside of the US. The company recently filed for the CE Mark on LockeT.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:43 pm

SPRC

SciSparc Ltd. (NASDAQ:SPRC) has received approval from the Federal Institute for Drugs and Medical Devices in Germany for its phase IIb clinical trial of SCI-110, a drug for treating adults with Tourette syndrome. The trial will be conducted at three global centers of excellence, including the Yale Child Study Center, the Hannover Medical School, and the Tel Aviv Sourasky Medical Center. The company has secured the necessary approvals from all three clinical sites and the Israeli Ministry of Health.

Portfolio Pulse from Vuk Zdinjak

July 03, 2023 | 12:39 pm

BIIB

IONS

NVS

Biogen Inc has announced new data on its drug Spinraza, showing improved motor function in infants and toddlers with spinal muscular atrophy (SMA) who had previously been treated with Novartis AG's gene therapy, Zolgensma. The data comes from an ongoing two-year, phase 4 open-label study. Analysts from William Blair suggest that the results indicate the added benefit of Spinraza treatment and predict that it will remain a significant contributor to Biogen's revenues, as well as those of its development partner, Ionis Pharmaceuticals Inc.

Portfolio Pulse from Vandana Singh

July 03, 2023 | 12:36 pm

RIVN

Rivian Automotive, Inc. (NASDAQ:RIVN) has announced its Q2 2023 production totals, producing 13,992 vehicles and delivering 12,640 vehicles. The company is on track to meet its 50,000 annual production guidance. Rivian will release its Q2 2023 financial results on August 8th.

Portfolio Pulse from Happy Mohamed

July 03, 2023 | 12:35 pm

CHRS

Coherus has launched YUSIMRY, a biosimilar of Humira, in the U.S. at a price of $995 per carton, representing a discount of over 85% compared to Humira. This move is expected to meet a high unmet need by providing patients, employers, physicians, and payers with low-cost access to adalimumab treatment.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:32 pm

RCON

Recon Technology, Ltd (NASDAQ:RCON) has announced a strategic partnership with Changxia Digital Energy Technology Co., Ltd., an affiliate of China Three Gorges Corporation. The partnership aims to leverage gas station resources to upgrade them to provide charging and other services to non-oil vehicle owners. The collaboration will focus on several key areas, including PV-to-electric vehicle charging, energy storage, multi-energy microgrids, hydrogen-electric integration, and virtual power plants.

Portfolio Pulse from Happy Mohamed

July 03, 2023 | 12:31 pm

MYO

Myomo, Inc. (NYSE:MYO), a wearable medical robotics company, has announced that its request to the Centers for Medicare and Medicaid Services (CMS) to classify the company's MyoPro as a brace has been published for public comment. If the proposal is finalized, MyoPro will be reimbursed by CMS in a lump-sum payment rather than as a rental. The proposed rule is expected to be finalized following a 60-day public comment period.

Portfolio Pulse from Happy Mohamed

July 03, 2023 | 12:30 pm